市场调查报告书
商品编码
1562240
2030 年亚太地区近视治疗市场预测 - 区域分析 - 按类型、治疗、年龄层和最终用户Asia Pacific Myopia Treatment Market Forecast to 2030 - Regional Analysis - by Type, Treatment, Age Group, and End User |
2022年亚太近视治疗市值为30.9716亿美元,预计2030年将达63.4864亿美元;预计2022年至2030年复合年增长率为9.4%。
用于治疗目标近视的先进技术的不断增加推动了亚太地区近视治疗市场的发展
用于治疗目标近视的先进技术的不断增加对于近视治疗市场来说是一个重大机会。雷射辅助原位角膜磨镶术 (LASIK)、屈光性角膜切除术 (PRK) 和植入式人工水晶体 (ICL) 等技术的进步使得更有效地矫正近视成为可能,且併发症更少。大会期间也提出了各种突破性资料;由 Johnson & Johnson Vision 支援的 30 多篇摘要已获批准展示。外科医师可以应用创新的 SILK(即平滑切口透镜状角膜磨镶术)治疗来治疗患有散光或不使用 ELITA™ 平台的近视患者。 ELITATM 平台凭藉其快速雷射传输技术和超精确雷射脉衝,为外科医生提供了极其顺利且简单的晶状体切除手术,并具有第二天的结果和康復效果。传统上,这些先进技术价格昂贵,许多患者无法取得。儘管如此,随着它们变得越来越广泛,它们为近视治疗市场提供了扩大其覆盖范围并为更多患者群体提供更好的治疗选择的机会。除了这些先进技术之外,其他新兴治疗方法,如角膜塑形术 (ortho-k) 和阿托品滴眼液,作为控制近视的有效方法也越来越受欢迎。这款广受欢迎的角膜塑形镜是获得 CE 标誌的最新 CooperVision 近视控制产品,加入了 EyeDream 和 Paragon CRT 角膜塑形镜设计、MiSight 日间软性隐形眼镜和 SightGlass 视觉扩散光学技术眼镜镜片。这些非侵入性治疗比手术治疗更便宜,使更多患者可以使用它们。总体而言,用于治疗目标近视的先进技术的不断增加为近视治疗市场提供了重大机会。透过为患者提供更有效、更容易获得的治疗选择,该市场可以帮助改善视力健康结果,并解决全球医疗保健领域未满足的重大需求。
亚太近视治疗市场概况
亚太近视治疗市场分为中国、日本、印度、澳洲、韩国和亚太其他地区。由于该地区人口老化加剧、研究数量不断增加、政府支持力度加大以及眼部相关疾病增多,2022年该地区将占亚太近视治疗市场的30.14%以上。
在亚太地区,2022年,中国在亚太近视治疗市场中占据最大的市场份额。例如,根据人口资料局2020年发布的一项研究,到2050年,中国老年人口预计将达到约3.66亿。 此外,根据同样的估计,中国约26%的人口将超过到2050 年,这一数字将从2020 年的12% 上升到65 %。中国近视盛行率也大幅上升,尤其是儿童,可能会增加中国近视治疗的采用。例如,根据《英国眼科杂誌》的数据,2019年中国学龄前儿童和中小学生近视盛行率为50.2%。此外,根据同一消息来源,2021年,6岁至16岁的儿童和青少年中有54.71%患有近视。
亚太地区近视治疗市场收入及 2030 年预测(百万美元)
亚太地区近视治疗市场区隔
亚太地区近视治疗市场按类型、治疗、年龄层、最终用户和国家分类。
根据类型,亚太近视治疗市场分为高度近视、退化性近视和进行性近视。 2022 年,高度近视细分市场占据亚太地区最大的近视治疗市场。
在治疗方面,亚太近视治疗市场分为低剂量阿托品眼药水、隐形眼镜、角膜塑形镜和屈光手术。 2022年,低剂量阿托品眼药水细分市场占据亚太地区最大的近视治疗市场。
依年龄组别划分,亚太近视治疗市场分为成人近视和儿童近视。 2022 年,成人近视细分市场将占据亚太地区近视治疗市场更大份额。
根据最终用户,亚太近视治疗市场分为医院和诊所、专科诊所和屈光手术中心。 2022年,医院和诊所细分市场占据亚太地区最大的近视治疗市场。
依国家/地区划分,亚太地区近视治疗市场分为澳洲、中国、日本、印度、韩国和亚太地区其他地区。 2022年,中国在亚太近视治疗市场份额中占据主导地位。
Bausch Health Companies Inc、Alcon AG、CooperVision Inc、Johnson & Johnson Vision Care Inc、Nidek Co Ltd、Haag-Streit AG 和 Carl Zeiss AG 是亚太近视治疗市场上的一些领先公司。
The Asia Pacific myopia treatment market was valued at US$ 3,097.16 million in 2022 and is expected to reach US$ 6,348.64 million by 2030; it is estimated to register a CAGR of 9.4% from 2022 to 2030.
Rising Availability of Advanced Technologies for Treating the Targeted Myopia Boosts Asia Pacific Myopia Treatment Market
The rising availability of advanced technologies for treating targeted myopia is a significant opportunity for the myopia treatment market. Advances in technologies such as laser-assisted in-situ keratomileusis (LASIK), photorefractive keratectomy (PRK), and implantable collamer lenses (ICL) have made it possible to correct myopia more effectively and with fewer complications. Various ground-breaking data were also presented during the congress; over 30 abstracts backed by Johnson & Johnson Vision have been approved for presentation. Surgeons can apply the innovative SILK (i.e., Smooth Incision Lenticule Keratomileusis) treatment to treat myopic patients who have astigmatism or do not utilize the ELITATM Platform. The ELITATM Platform offers surgeons an exceptionally smooth and uncomplicated lenticular removal procedure with next-day outcomes and recovery owing to its fast laser delivery technology and ultra-precise laser pulse. These advanced technologies have traditionally been expensive and inaccessible to many patients. Still, as they become more widely available, they present an opportunity for the myopia treatment market to expand its reach and provide better treatment options to a larger patient population. In addition to these advanced technologies, other emerging treatments such as orthokeratology (ortho-k) and atropine eye drops are gaining popularity as effective methods for managing myopia. The popular orthokeratology contact lens is the latest CooperVision myopia control product to gain the CE Mark, joining EyeDream and Paragon CRT ortho-k designs, MiSight day soft contact lenses, and SightGlass Vision Diffusion Optics Technology spectacle lenses. These non-invasive treatments can be more affordable than surgical options, making them accessible to a wider range of patients. Overall, the rising availability of advanced technologies for treating targeted myopia presents a significant opportunity for the myopia treatment market. By providing patients with more effective and accessible treatment options, the market can help improve vision health outcomes and address a significant unmet need in the global healthcare landscape.
Asia Pacific Myopia Treatment Market Overview
Asia Pacific myopia treatment market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. This region accounted for over 30.14% of the Asia Pacific myopia treatment market in 2022 owing to the increasing aging population, rising number of research studies, growing government support, and increasing eye-related disorders in the region.
In Asia Pacific, China held the largest market share for Asia Pacific myopia treatment market in 2022. The market growth is primarily attributed to the aging population, the increasing prevalence of myopia, and the rising emphasis on preventive care. For instance, according to a study published by the Population Reference Bureau in 2020, the old-age population of China is expected to reach ~366 million by 2050. Moreover, according to the same estimates, around 26% of China's population will be over 65 by 2050, up from 12% in 2020. Such an extensively increasing geriatric population is anticipated to offer lucrative opportunities for the increased demand for products in the country. The country is also witnessing considerable growth in the prevalence of myopia, particularly in children, which is likely to increase the adoption of treatments in China. For instance, preschoolers and primary and secondary school students in China had a 50.2% prevalence of myopia in 2019, according to the British Journal of Ophthalmology. Additionally, according to the same source, 54.71% of children and adolescents between the ages of 6 and 16 had myopia overall in 2021. Thus, the increasing geriatric population and the increasing prevalence of myopia are driving the market growth.
Asia Pacific Myopia Treatment Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Myopia Treatment Market Segmentation
The Asia Pacific myopia treatment market is categorized into type, treatment, age group, end user, and country.
Based on type, the Asia Pacific myopia treatment market is segmented into high myopia, degenerative myopia, and progressive myopia. The high myopia segment held the largest Asia Pacific myopia treatment market share in 2022.
In terms of treatment, the Asia Pacific myopia treatment market is segmented into low-dose atropine eye drops, contact lenses, ortho-k, and refractive surgery. The low-dose atropine eye drops segment held the largest Asia Pacific myopia treatment market share in 2022. Furthermore, the refractive surgery segment is subcategorized into LASIK and PRK.
By age group, the Asia Pacific myopia treatment market is bifurcated into adult myopia and childhood myopia. The adult myopia segment held a larger Asia Pacific myopia treatment market share in 2022.
Based on end user, the Asia Pacific myopia treatment market is categorized into hospitals and clinics, specialty clinics, and refractive surgery centers. The hospitals and clinics segment held the largest Asia Pacific myopia treatment market share in 2022.
Based on country, the Asia Pacific myopia treatment market is categorized into Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific myopia treatment market share in 2022.
Bausch Health Companies Inc, Alcon AG, CooperVision Inc, Johnson & Johnson Vision Care Inc, Nidek Co Ltd, Haag-Streit AG, and Carl Zeiss AG are some of the leading companies operating in the Asia Pacific myopia treatment market.